Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Operating Expenses (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Operating Expenses for 12 consecutive years, with $160.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses changed 0.02% to $160.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $666.9 million, a 19.22% increase, with the full-year FY2025 number at $666.9 million, up 19.22% from a year prior.
  • Operating Expenses was $160.2 million for Q4 2025 at Iovance Biotherapeutics, down from $162.4 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $173.7 million in Q2 2025 to a low of $86.3 million in Q2 2023.
  • A 3-year average of $138.7 million and a median of $140.3 million in 2024 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: surged 54.05% in 2024, then decreased 0.02% in 2025.
  • Iovance Biotherapeutics' Operating Expenses stood at $121.7 million in 2023, then soared by 31.65% to $160.3 million in 2024, then fell by 0.02% to $160.2 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Operating Expenses are $160.2 million (Q4 2025), $162.4 million (Q3 2025), and $173.7 million (Q2 2025).